Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ESRRA | P11474 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30376409 | 1.00 | AR (0.51) | ARALKCYP11B2EGLN2CYP11B1 | |
| SCHEMBL27439951 | 0.85 | KIT (0.46) | ARALKKDM1AMAPTALDH1A1 | |
| SCHEMBL30870706 | 0.85 | KIT (0.46) | ARALKKDM1AMAPTALDH1A1 | |
| SCHEMBL708391 | 0.84 | AR (0.51) | ARALKEGLN2KDM1APOLB | |
| SCHEMBL30118209 | 0.84 | AR (0.51) | ARALKEGLN2KDM1APOLB | |
| SCHEMBL5472622 | 0.83 | AR (0.53) | ARALKCYP11B2CYP11B1MAPT | |
| SCHEMBL31355171 | 0.82 | CYP11B1 (0.44) | ARALKCYP11B2EGLN2CYP11B1 | |
| SCHEMBL2888669 | 0.81 | ALDH1A1 (0.45) | ARALKKDM1AMAPTPOLB | |
| SCHEMBL509522 | 0.81 | AR (0.66) | ARCYP11B2EGLN2CYP11B1KDM1A | |
| SCHEMBL29490258 | 0.81 | AR (0.66) | ARCYP11B2EGLN2CYP11B1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025081982-A1 | PREPARATION METHOD FOR FINERENONE KEY INTERMEDIATE | 山东诚创蓝海医药科技有限公司 | 2025-04-24 | — | — | WO | claimed |
| CN-119859112-A | Preparation method of non-neridrone key intermediate | 山东诚创蓝海医药科技有限公司 | 2025-04-22 | — | — | CN | claimed |
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH S L (ES) | 2026-05-21 | — | — | US | disclosed |
| US-12540133-B2 | Potent and selective compounds as serotonin 1B receptor modulators | LEUKOS BIOTECH, S.L. (ES) | 2026-02-03 | — | — | US | disclosed |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2025081982-A1 | PREPARATION METHOD FOR FINERENONE KEY INTERMEDIATE | 山东诚创蓝海医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| WO-2025081982-A1 | PREPARATION METHOD FOR FINERENONE KEY INTERMEDIATE | 山东诚创蓝海医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-119859112-A | Preparation method of non-neridrone key intermediate | 山东诚创蓝海医药科技有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119859112-A | Preparation method of non-neridrone key intermediate | 山东诚创蓝海医药科技有限公司 | 2025-04-22 | — | — | CN | disclosed |
| EP-4341264-B1 | PYRROLOPIRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LEISHMANIASIS | DRUGS FOR NEGLECTED DISEASES INITIATIVE (CH) | 2025-04-02 | — | — | EP | disclosed |
| WO-2007087488-A9 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2007087488-A2 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-02 | — | — | WO | disclosed |
| US-6849619-B2 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-6699852-B2 | ANTISEROTONIN AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-02 | — | — | US | disclosed |
| EP-1343791-A2 | SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-21 | — | — | US | disclosed |
| WO-2002059129-A2 | SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| CN-1055925-A | Pyridine derivate and preparation method thereof | ICI PLC (GB) | 1991-11-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | AR 2665/4885ALK 3175/4885CYP11B2 367/4885 |
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | HTR3B, HTR1B, HTR1A | AR 523/4885ALK 1637/4885CYP11B2 94/4885 |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | AR 2665/4885ALK 3175/4885CYP11B2 367/4885 |
| US-12540133-B2 | Potent and selective compounds as serotonin 1B receptor modulators | HTR3B, HTR1A, HTR1B | AR 291/4885ALK 1143/4885CYP11B2 100/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | AR 1849/4885ALK 24/4885CYP11B2 3139/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | AR 3783/4885ALK 3577/4885CYP11B2 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.